[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpes-zoster-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpes-zoster-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100619409","efficacy-and-safety-of-intravenous-dexamethasone-palmitate-treatments-in-acute-and-subacute-herpes-zoster-pain-100619409",false,"NCT07344246","Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain","Efficacy and Safety of Systemic Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain：a Randomized, Prospective, Multicenter, Blinded Endpoint, Open-label Controlled Trial","Inclusion Criteria:\n\n\\- 1. Patients with onset of HZ rash less than 90 days. 2. HZ affected the trigeminal nerves (ophthalmic\u002F maxillary\u002F mandibular nerve). 3. Aged 18 to 75 years (inclusive). 4. Pain intensity ≥ 7 cm on a visual analogue scale (VAS) with 0= 'no pain' to 10='unbearable pain'.\n\n5\\. Tender point count \\> 4. 6. Agreed to sign the informed consent form.\n\nExclusion Criteria:\n\n1. Infection at the puncture site.\n2. Poor general situation unable to be treated.\n3. A history of abuse of narcotics.\n4. Non-compliance or inability to complete the self-evaluation questionnaires.\n5. Pregnancy or lactation.\n6. Patients using immunosuppressants and those with severe systemic diseases such as hematological malignancies, cancers, or autoimmune disorders.","ALL","18 Years","75 Years",{"count":20,"type":21},954,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a randomized, prospective, multicenter, open-label, blinded-endpoint study investigating the efficacy and safety of dexamethasone palmitate (DXP) for treating acute and subacute herpes zoster (shingles) pain.\n\nThe study consists of four parallel sub-studies, each designed to answer a specific question:\n\nStudy 1: Compares intramuscular (IM) vs. intravenous (IV) administration of DXP (8mg) against standard therapy alone.\n\nStudy 2: Compares two different IV doses of DXP (4mg vs. 8mg) against standard therapy.\n\nStudy 3: For HZ on the body trunk, compares IM injection vs. tender point infiltration vs. paravertebral nerve block (all containing 8mg DXP).\n\nStudy 4: For HZ on the face (trigeminal nerve), compares IM injection vs. tender point infiltration vs. trigeminal nerve block (all containing 8mg DXP).\n\nApproximately 558 adult patients with HZ rash onset within 90 days and significant pain (VAS ≥7) will be enrolled across the studies. All patients receive standard background therapy, including antiviral medication (famciclovir), pregabalin, and rescue analgesics.\n\nThe primary outcome is the change in pain intensity (Visual Analogue Scale, VAS) over 6 months. Secondary outcomes include the incidence of postherpetic neuralgia (PHN) at 3 and 6 months, consumption of pain medications, patient satisfaction, quality of life, and safety.\n\nThe goal is to determine if DXP, through its targeted anti-inflammatory action, provides superior pain relief and PHN prevention compared to standard care, with a favorable safety profile across different administration routes.",[27],"Herpes Zoster Pain","NOT_YET_RECRUITING","2026-01-07",{"date":31,"type":32},"2026-01-15","ACTUAL",{"date":34,"type":21},"2026-02-01",{"date":36,"type":21},"2028-12-01",{"name":38,"class":39},"Beijing Tiantan Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100589802","phase-4-high-voltage-long-duration-pulsed-radiofrequency-combined-with-liposomal-bupivacaine-subcutaneous-block-for-herpes-zoster-associated-neuralgia-100589802","NCT06959147","High-Voltage Long-Duration Pulsed Radiofrequency Combined With Liposomal Bupivacaine Subcutaneous Block for Herpes Zoster-Associated Neuralgia","Inclusion Criteria:\n\nPatients diagnosed with zoster-associated neuralgia (ZAN) who meet ALL of the following conditions:\n\n* Voluntarily provided written informed consent.\n* Inadequate response to pharmacological or other non-surgical therapies OR intolerable drug-related adverse effects.\n* Herpes zoster (HZ) lesions involving cranial\u002Fcervicocephalic, cervical, thoracic, or lumbar dermatomes.\n* Moderate-to-severe pain intensity, defined as a Numerical Rating Scale (NRS) score ≥4 at baseline.\n* Aged between 40 and 85 years.\n* Body weight: Male ≥50 kg; female ≥45 kg.\n\nExclusion Criteria:\n\n* Severe cardiovascular diseases or life-threatening arrhythmias (e.g., heart failure, third-degree atrioventricular block without pacemaker implantation).\n* Contraindications to minimally invasive interventions (e.g., coagulation disorders, active infections).\n* Allergy to local anesthetics or lipid emulsions; Severe dysfunction of vital organs (cardiac, pulmonary, hepatic, or renal) rendering the patient unfit for the procedure.\n* Severe endocrine disorders or long-term use of corticosteroids\u002Fimmunosuppressive agents.\n* Cognitive impairment or inability to cooperate with treatment protocols.\n* Prior history of neuromodulation therapies (e.g., spinal cord stimulation or pulsed radiofrequency (PRF) treatment).","40 Years","85 Years",{"count":50,"type":21},46,[52],"PHASE4","Research Objectives Background and Significance: Zoster-associated neuralgia (ZAN) refers to neuropathic pain experienced by herpes zoster (HZ) patients before, during, and after rash resolution, characterized by paroxysmal, lightning-like, or knife-like sensations. Postherpetic neuralgia (PHN), a common type of chronic pain, is often accompanied by physical-psychological impairments, social dysfunction, and anxiety-depression. While high-voltage long-term pulsed radiofrequency (HL-PRF) has become a conventional treatment for ZAN, it is limited by residual postoperative localized pain and suboptimal efficacy for refractory cases. Liposomal bupivacaine (LB), a sustained-release analgesic providing up to 72 hours of pain relief, offers potential for combined subcutaneous injection to enhance symptomatic control.\n\nStudy Process:\n\nThis clinical study focuses on evaluating the efficacy of HL-PRF combined with LB subcutaneous injection in treating ZAN. The trial will be conducted from December 16, 2024, to December 14, 2026, with an anticipated enrollment of 92 participants. Patients will be randomized into two groups:\n\nHL-PRF group: Under CT-guided localization, high-voltage pulsed radiofrequency (HL-PRF) therapy was precisely delivered to the pathologically compromised dorsal root ganglion (DRG).\n\nHL-PRF+LB group: HL-PRF treatment followed by LB subcutaneous injection at the painful lesion site 2 hours post-procedure.\n\nClinical data will be collected preoperatively, and inflammatory factors will be assessed on the first postoperative day. Follow-up evaluations via telephone will occur at 1 week, 1 month, 3 months, and 6 months postoperatively. By analyzing changes in observed indicators before and after treatment, this study aims to determine the clinical efficacy of combining HL-PRF with LB subcutaneous injection for ZAN.",[27,55],"Neuralgia, Postherpetic","RECRUITING","2025-04-27",{"date":59,"type":32},"2025-05-06",{"date":61,"type":32},"2024-12-17",{"date":63,"type":21},"2026-05-31",{"name":65,"class":39},"Shirong Tan",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100588546","the-efficacy-of-high-frequency-short-time-spinal-cord-stimulation-in-the-treatment-of-herpes-zoster-associated-neuralgia-100588546","NCT06942806","The Efficacy of High-frequency Short-time Spinal Cord Stimulation in the Treatment of Herpes Zoster-associated Neuralgia","Inclusion Criteria:\n\n1. Patients with inadequate response to non-surgical treatments such as pharmacotherapy;\n2. Patients with major organ dysfunction intolerant to drug therapy;\n3. Patients with systemic comorbidities (e.g., hypertension, diabetes mellitus);\n4. Patients with moderate to severe pain intensity (Numerical Rating Scale \\[NRS\\] score ≥ 4).\n\nExclusion Criteria:\n\n1. Patients with severe psychiatric disorders;\n2. Patients with severe local or systemic infections at the puncture site;\n3. Patients with severe coagulopathies (platelet count \\\u003C 80×10⁹\u002FL during puncture) or those requiring uninterrupted anticoagulation therapy without bridging protocol;\n4. Patients with end-stage organ failure who cannot maintain prone positioning or tolerate the procedure;\n5. Patients with severe spinal stenosis, vertebral ankylosis, or scoliosis;\n6. Patients with language barrier or impaired communication abilities.ion",{"count":73,"type":21},74,"OBSERVATIONAL","Zoster-associated neuralgia (ZAN) is a type of neuropathic pain caused by the reactivation of the varicella-zoster virus (VZV). The global annual incidence is approximately 3-5 per 1,000 individuals, and in China, the incidence is around 4.89 per 1,000 individuals, increasing with age. The underlying mechanisms of ZAN involve neuroinflammation, peripheral and central sensitization, and other factors, ultimately leading to anxiety, depression, and significant reductions in quality of life. Treating ZAN remains challenging.\n\nSpinal cord stimulation (SCS) alleviates pain via multiple mechanisms, including the gate control theory, modulation of neurotransmitters (e.g., gamma-aminobutyric acid), suppression of neuroinflammation (e.g., reduced levels of IL-1β and TNF-α), and promotion of autophagy. However, traditional low-frequency SCS (30-100 Hz) is limited by incomplete pain coverage, reduced long-term efficacy, and side effects such as paresthesia (e.g., tingling sensations).\n\nHigh-frequency SCS (HF-SCS, 1,000 Hz) offers pain relief without inducing paresthesia. Studies have suggested that it may be superior to traditional SCS. However, clinical data on the use of HF-SCS in ZAN are limited, and no such studies have been conducted in China.\n\nThis study aims to compare the efficacy of short-term high-frequency (1 kHz) SCS with traditional low-frequency SCS in the treatment of ZAN. By evaluating outcomes such as pain relief (NRS scores), improvements in anxiety and depression (HADS), sleep quality (PSQI), patient-reported experience, and complication rates, this research seeks to assess the safety and efficacy of short-term HF-SCS, thereby potentially providing a novel therapeutic strategy for patients with ZAN.",[27],[78,79,80,81],"Spinal cord stimulation","Herpes zoster-associated neuralgia","Neuromodulation","High-frequency spinal cord electrical stimulation","2025-04-25",{"date":84,"type":32},"2025-04-30",{"date":86,"type":32},"2024-02-01",{"date":88,"type":21},"2025-05-31",{"name":90,"class":39},"Li Zhao"]